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Background: With high throughput screening, novel therapeutic agents can be efficiently identified. Unfortunately,
researchers only resort to in vitro cell viability assays for screening of anticancer drugs for retinoblastoma, the most
common intraocular cancer in the childhood. Current available animal models of retinoblastoma require more than 2
weeks for tumour formation and the investigation of the efficacy of therapeutic agents. In this study, we established a
novel orthotopic transplantation model of retinoblastoma in zebrafish as an in vivo animal model for screening of
anticancer drugs.
Methods: We injected retinoblastoma cells into the vitreous cavity of zebrafish at 48 hours after fertilization.
Eyeballs of zebrafish were scanned daily under the confocal laser microscope, and the tumor population was
quantitatively analyzed by measuring the mean intensity of green fluorescent protein (GFP). Transplanted
retinoblastoma cells were isolated to perform further analyses including Western blotting and reverse
transcriptase-polymerase chain reaction to confirm that retinoblastoma cells maintained their characteristics as
tumor cells even after transplantation and further isolation. To figure out the potential of this model for screening
of anticancer drugs, zebrafish were cultured in Ringer’s solution containing carboplatin and melphalan after the
injection of retinoblastoma cells.
Results: The degree of the tumor population was dependent on the number of retinoblastoma cells injected and
maintained stably for at least 4 days. Transplanted retinoblastoma cells maintain their proliferative potential and
characteristics as retinoblastoma cells after isolation. Interestingly, systemic application of carboplatin and
melphalan demonstrated significant reduction in the tumor population, which could be quantitatively analyzed by
the estimation of the mean intensity of GFP.
Conclusions: This orthotopic retinoblastoma model in zebrafish is expected to be utilized for the screening of
anticancer drugs for the treatment of retinoblastoma.
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Figure 1 Human retinoblastoma cells are injected into the
vitreous cavity of zebrafish embryo at 48 hpf. Via glass capillaries
attached to the microinjector with the pneumatic pump system,
retinoblastoma cells are injected into the vitreous cavity of zebrafish
embryo (A). 4- μm thin paraffin section demonstrates the existence
of retinoblastoma cells 2 days after the injection in the vitreous
cavity, the bowl-like hollow space between the lens and the retina
(B). Scale bar, 100 μm.
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For the effective treatment of cancer, it is crucial to select
proper regimens of anticancer drugs, which are based on
the robust development of various regimens to improve ef-
ficacy and minimize toxicity. Last few decades are
blossomed with the introduction of novel therapeutics
such as targeted therapy or immunotherapy for cancers
[1,2]. In the pediatric cancers, there are also many at-
tempts for the introduction and actual uses of novel thera-
peutics [3]. Unfortunately, that was not the case in the
treatment of retinoblastoma, the most common intraocu-
lar malignancy in childhood but an uncommon disease of
the incidence of 1/20,000 births worldwide [4,5]. Cur-
rently, carboplatin-based regimens are widely utilized in
the systemic chemotherapy and melphalan is commonly
employed in the intraarterial chemotherapy, which ad-
dresses the tumor by the administration of anticancer
drugs to ophthalmic artery via catheterization [6,7]. Al-
though these approaches have yielded satisfactory clinical
outcomes, there are still patients who are compelled to
undergo enucleation, the complete removal of the eyeball,
resulting in irreversible vision loss for the lifetime.
Novel therapeutic agents can enhance the efficacy of cur-
rently utilized administration modalities including intra-
venous, intraarterial, and intravitreal injection [8]. For the
development and screening of novel therapeutic agents,
the effective screening tools are desperately required. As
for retinoblastoma, a previous attempt on multiple screen-
ing of anticancer drugs simply utilized in vitro cell viability
assays and measurements of chemosensitivities in the hu-
man tumor clonogenic assay using primary retinoblastoma
cells and established cell lines [9]. However, there is no
effective in vivo animal model for multiple screening of an-
ticancer drugs at one time. Currently available animal
models including mice with genetic aberrations and mur-
ine orthotopic transplantation models require more than 2
weeks to form tumors; therefore, they are not suitable
for rapid and high throughput screening of anticancer
drugs [10,11].
In this study, we transplanted retinoblastoma cells
into the vitreous cavity of zebrafish to establish a novel
orthotopic transplantation model of retinoblastoma in
zebrafish that can be utilized for high throughput
screening of anticancer drugs. Zebrafish are suitable for
extensive testing of multiple drugs because of relatively
low maintenance cost, accessibility of in vivo imaging,
and tiny size [12,13]. Especially, we investigated the po-
tential of orthotopic transplantation of retinoblastoma
to mimic the tumor microenvironment as much as pos-
sible. In addition, we can quantitatively analyze the de-
gree of the tumor population in this model with a
public image processing program. Furthermore, there is
no change in the characteristics of tumor cells between
before and after the injection, demonstrating thestability of transplanted cells as tumor cells during the
study. Also, we identified the possibility of this model as
a screening tool for various anticancer drugs with 2
widely utilized anticancer drugs for retinoblastoma,
carboplatin and melphalan.
Results
Human retinoblastoma cells are injected into the vitreous
cavity of zebrafish embryo at 48 hpf
To establish the orthotopic transplantation model of ret-
inoblastoma in zebrafish, we injected retinoblastoma
cells into the vitreous cavity of zebrafish embryo at 48
hours post fertilization (hpf ) (Figure 1A). Normally, the
larval pigment pattern of zebrafish was developed com-
pletely within 6 days after fertilization [14]; therefore N-
phenylthiourea (PTU) was used 1 day after fertilization
to inhibit pigmentation of the eyeballs of zebrafish to
maximize the visibility of the tumor population under the
confocal laser microscope. PTU of the concentration uti-
lized in this study (0.2 mM) did not show inhibitory effect
on the proliferation of retinoblastoma cells by itself (data
not shown). In zebrafish, the vitreous cavity is a bowl-like
hollow space between the lens and the retina. When the
cells were adequately injected into this space, they could
spread along the vitreous cavity and maintain their popula-
tion. As shown in Figure 1B, retinoblastoma cells showed
stable maintenance in the vitreous cavity of zebrafish 2
days after the injection (days post injection, dpi).
The degree of the tumor population is dependent on the
number of retinoblastoma cells injected
To figure out the potential of the quantification of the
data in this novel zebrafish model of retinoblastoma, we
intravitreally injected retinoblastoma cells, SNUOT-Rb1
cells which we previously established [15], of different
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variations between injections, we performed injection
on over 200 zebrafish at a sitting with the pneumatic
pump system. With the aid of microinjectors with glass
capillaries and the regulator of injection pressure in the
pneumatic pump system, we could minimize the intra-
experiment and inter-experiment variations. For the
quantification of the data, the mean intensity of green
fluorescent protein (GFP) expression was measured
using ImageJ software.
As expected, the degree of the tumor population was
determined by differential amount of retinoblastoma cells
injected (Figure 2C). The mean intensity of GFP expression
was selected as the representative value for the tumor
population instead of the total area of GFP expression in
that the total area only represented the 2-dimensional dis-
tribution of tumor cells, not the 3-dimensional constitution
of them. Interestingly, the degree of the tumor population
was maintained from 1 dpi to 4 dpi (Figure 2C). The stable
maintenance of the tumor population and the differential
population according to the number of injected cells are 2Figure 2 The degree of the tumor population is dependent on the nu
retinoblastoma cells into the vitreous cavity of zebrafish, and the eyeballs o
microscope 20 cells, (A; 100 cells, B). Scale bar, 100 μm. The tumor populat
expression at 4 dpi with the public image processing program, ImageJ (C).
experiments. dpi, day(s) post injection; GFP, green fluorescent protein.important characteristics that make up the potential of this
method of orthotopic transplantation of retinoblastoma
cells as an animal model of retinoblastoma.Transplanted retinoblastoma cells are successfully
isolated and maintain their characteristics as tumor cells
As shown in Figure 2C, the tumor population was main-
tained from 1 dpi to 4 dpi. This phenomenon may be due
to the stability of this model system; however, it can be
due to the alteration of the characteristics of tumor cells
after the transplantation into the vitreous cavity. To verify
that the transplanted cells retained their characteristics as
retinoblastoma cells, we isolated retinoblastoma cells at
4 dpi from the zebrafish. Because we transduced GFP
containing lentiviral particles into the cells before trans-
plantation, we could identify transplanted cells by con-
firming the expression of GFP. Furthermore, the selection
media containing puromycin was utilized throughout the
isolation process to selectively isolate transplanted retino-
blastoma cells. As expected, the morphology ofmber of retinoblastoma cells injected. We injected 20 and 100
f zebrafish embryos were scanned daily through the confocal laser
ion was quantitatively analyzed as the mean intensity of GFP
Data of 8 zebrafish per group from at least 2 independent
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and further isolation (Figure 3A and B). To demonstrate
the maintenance of previously reported biochemical char-
acteristics of SNUOT-Rb1 cells after the transplantation
and isolation [15], we performed Western blot for glial fi-
brillary acidic protein (GFAP, glial differentiation marker)
and neuron-specific enolase (NSE, neuronal differentiation
marker), demonstrating no change between SNUOT-Rb1
cells and isolated cells (Figure 3C). These patterns demon-
strated that transplanted cells retained the characteristics of
blastoma cells that shared glial and neuronal differentiation
markers. The expression of cellular retinaldehyde-binding
protein (CRALBP), the marker of retinal constituent cells,
also exhibited no definite change between 2 types of cells
(Figure 3D).Figure 3 Transplanted retinoblastoma cells are successfully isolated a
and further isolation of retinoblastoma cells do not induce morphological
transplantation and isolation, B). Scale bar, 100 μm. Western blotting for gl
NSE demonstrates no definite change between preinjected and isolated re
gene, a marker for retinal constituent cells (D). As with the first injection of
stable tumor population 2 days after the injection First injection, (E; Reinjec
zebrafish into which SNUOT-Rb1 cells were injected.The potential of formation of the tumor population
was examined by reinjecting isolated cells into the vitre-
ous cavity of zebrafish. Similarly with the first injection
(Figure 3E), reinjection of retinoblastoma cells effectively
induced the tumor population (Figure 3F). Further culti-
vation of isolated cells showed that the cells retained
unique characteristics of SNUOT-Rb1 cells of adherent
and rapid growth.A novel orthotopic retinoblastoma model in zebrafish can
be utilized for the screening of anticancer drugs
We established this orthotopic retinoblastoma model in
zebrafish with the purpose of utilizing for the screening of
anticancer drugs. Carboplatin and melphalan were selectednd maintain their characteristics as tumor cells. Transplantation
changes in retinoblastoma cells Before injection, (A; After
ial differentiation marker, GFAP and neuronal differentiation marker,
tinoblastoma cells (C). RT-PCR shows stable expression of CRALBP
retinoblastoma cells, reinjection of isolated cells demonstrates the
tion of isolated cells, F). Scale bar, 100 μm. Rb1-Zf, isolated cells from
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one of the main anticancer drugs in the regimens for sys-
temic chemotherapy [7], and melphalan is widely utilized
in the regimen for intraarterial chemotherapy, which aims
at the control of primary tumor or subretinal and vitreous
seedings [16,17]. The treatment of retinoblastoma cells
with carboplatin and melphalan for 48 hours induced re-
duction in the cell viability by 74% and 61% at the concen-
tration of 200 μM, respectively (Figure 4A). As we observe
in the clinical settings, these therapeutic agents showed in-
hibitory effect on proliferation of SNUOT-Rb1 cells.Figure 4 A novel orthotopic retinoblastoma model in zebrafish can b
are treated with carboplatin and melphalan of various concentrations from
diluted in fresh Ringer’s solution induces reduction of the tumor populatio
bar, 100 μm. Quantitative analysis of the tumor response in this model yiel
independent experiments. dpi, day(s) post injection; GFP: green fluorescentSimilarly with in vitro antiproliferative effect, 2 antican-
cer drugs demonstrated to reduce the tumor population
in zebrafish (Figure 4B and C). To demonstrate anticancer
activity of both drugs, zebrafish were cultured in Ringer’s
solution containing 200 μM anticancer drugs right after
the injection of 100 retinoblastoma cells. As shown in
Figure 4B and C, therapeutic agents seemed to induce dis-
persion of retinoblastoma cells, not joining as a tumor in
Figure 2B. We also compared the mean intensity of GFP
expression between the control and the treatment groups.
As expected, carboplatin and melphalan reduced thee utilized for screening of anticancer drugs. Retinoblastoma cells
25 to 400 μM (A). Systemic application of both anticancer drugs
n in zebrafish Carboplatin treatment, (B; Melphalan treatment, C). Scale
ds stable results (D). Data of 8 zebrafish per group from at least 2
protein.
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(P = 0.0312), respectively, compared to the control
(Figure 4D). Like in these examples of carboplatin and
melphalan, anticancer drugs can be screened in this novel
orthotopic transplantation model for retinoblastoma in
zebrafish.
Discussion
The development of novel effective regimens is one of the
best parts in the treatment of cancer. In addition, the in-
vestigation into proper administration options is required
in localized tumors such as retinoblastoma, which origi-
nates from the inner layers of the retina and extends into
the adjacent structures such as vitreous cavity, optic nerve,
and choroid [18,19]. In this regard, researchers on the
treatment of retinoblastoma have struggled to find novel
therapeutic agents and modalities to deliver anticancer
drugs to tumors. Particularly, current studies are mainly
focused on the development and validation of novel thera-
peutic modalities such as intraarterial and intravitreal
chemotherapy plus conventional intravenous chemother-
apy [8]. With these efforts, tumors of group A to C
according to the International Classification of Retino-
blastoma (ICR) demonstrate the treatment success rate of
over 90% by intravenous chemotherapy with carboplatin,
vincristine, and etoposide [6]; intraarterial chemotherapy
with melphalan can be utilized as salvage treatment after
chemoreduction failure or primary treatment for advanced
stages, group D or E according to the ICR [8]. However,
studies on the novel therapeutic agents for retinoblastoma
slightly lag behind compared to rapid increase in the
development and introduction of targeted therapy or
immunotherapy in other pediatric cancers [3]. Still, enu-
cleation is the last choice for treatment failure with
chemotherapy of various administration modalities; there-
fore, we speculated that the introduction of novel antican-
cer drugs might improve the clinical outcomes of current
available modalities, minimizing the risk of irreversible vi-
sion and eyeball loss.
For the development of novel therapeutic agents, mul-
tiple screening of various candidate drugs is required. Once
several candidate drugs are selected from in vitro experi-
ments, adequate in vivo studies should be performed for
identification of better drugs in animal models. However,
current animal models of retinoblastoma are not suitable
for high throughput screening of drugs in that tumor is
formed after more than 2 weeks and we cannot perform
experiments on many mice at one time. For example, the
orthotopic transplantation model in mice requires 4 to 8
weeks to demonstrate the efficacy of anticancer drugs,
although the tumor formation is evident in all the pups
[10]. Similarly, researchers wait 2 weeks after the birth to
form tumors in a genetic mouse model of retinoblastoma
(Chx10-Cre;Rb(lox/lox);p107(−/−);p53(lox/lox)) [11].In this study, we completed 1 round of experiments
within 1 week after the fertilization and performed injec-
tion of retinoblastoma cells into the vitreous cavity on
more than 200 zebrafish at a sitting. Transplantation of
tumor cells to zebrafish has been utilized for investiga-
tion of tumor biology [20,21]. In addition, a few attempts
explored the possibility of zebrafish models as tools
for screening of anticancer drugs [13,22,23]. In these
models, tumor cells from oral squamous cell carcinoma
and leukemia cell lines are injected through yolk sac.
We attempted the different approach from these studies
in that we injected tumor cells into the vitreous cavity,
with which retinoblastoma interacts in real patients. As
shown in Figure 1, we successfully injected tumor cells
into the vitreous cavity of zebrafish embryos at 48 hpf.
Interestingly, the highest increase in the GFP expres-
sion occurred between 0 dpi and 1 dpi and the level of
GFP expression maintained stably throughout the study
period, when we quantitatively analyzed the data. We
speculated the presumptive reasons of this phenomenon
as follows: 1) right after the injection, tumor cells might be
inevitably packed. The emission of fluorophores might be
interfered by other obscuring tumor cells or intraocular
structures such as the lens in front of tumor cells when we
observed the cells under the confocal laser microscope. 2)
In this regard, after the redistribution of tumor cells from
0 dpi to 1 dpi, the expression of GFP was increased.
The more important part with the alterations of GFP ex-
pression is that there was stable expression of GFP be-
tween 1 dpi and 4 dpi. In the normal culture condition,
SNUOT-Rb1 cells double their numbers every 24 hours
[14]. However, in the vitreous cavity of zebrafish and pre-
vious murine models of mice, doubling of tumor cells is
not that fast [10]. The interaction between the tumor and
the vitreous might be different from that between the
tumor and the culture media.
The distribution patterns as well as the mean intensity
of GFP expression were different according to the number
of injected cells. We can observe dispersed cells when we
injected only 20 cells (Figure 2A). In contrast, the injection
of 100 retinoblastoma cells induced more ordered distri-
bution of tumor cells as shown in Figures 2B and 3E. So
we decided to inject 100 cells for further experiments on
investigating into the potential of this model for screening
of anticancer drugs.
Interestingly, we found the potential of this model as a
tool for multiple screening of anticancer drugs with
carboplatin and melphalan. We necessarily selected these 2
currently utilized drugs because they are widely utilized in
real clinical settings for retinoblastoma patients. Interest-
ingly, both drugs demonstrated effective anticancer activity
on this model. These results might provide the possibility
of this model as a screening tool for the evaluation of anti-
cancer drugs which are in the development process.
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than 200 zebrafish embryos at a sitting; therefore, more
than 20 different candidate drugs can be screened with 1
session of experiments. Quantitative analysis of the tumor
population yielded stable and reproducible results, demon-
strating the usefulness of this model. After the image was
captured with the confocal laser microscope, the quantita-
tive data can be easily obtained with the public image pro-
cessing program, ImageJ, by a few clicks.
Conclusions
In this model, we performed orthotopic transplantation of
retinoblastoma cells into the vitreous cavity of zebrafish.
In this novel animal model of retinoblastoma, it was pos-
sible to quantitatively analyze the tumor population and
the response of tumors to anticancer drugs with a public
image processing program. Transplanted retinoblastoma
cells retained their characteristics as tumor cells during
the study period. We speculated that this novel orthotopic
transplantation model for retinoblastoma in zebrafish can
be a gateway for the development of anticancer drugs for
retinoblastoma, one of the tumors that lag behind in the




Adult wild-type zebrafish, purchased from a local aquar-
ium farm and maintained in the laboratory facility, were
utilized for producing embryos by breeding. Zebrafish were
raised at 28.5°C in alternate dark–light cycles of 13 and 11
hours, respectively. Twenty-four hours after fertilization,
zebrafish embryos were placed in fresh Ringer’s solution
with 0.2 mM PTU (Sigma-Aldrich, St. Louis, MO) to in-
hibit pigmentation of eyeballs. Care, use, and treatment of
animals were done in agreement with the Association for
Research in Vision and Ophthalmology for the use of ani-
mals in ophthalmic and vision research and the guidelines
established by the Seoul National University Institutional
Animal Care and Use Committee.
Cell culture
SNUOT-Rb1 cells, from the previously established ret-
inoblastoma cell line by our group [15], were main-
tained in RPMI 1640 medium (WelGENE, Daegu,
Korea) supplemented with 10% fetal bovine serum (FBS;
Gibco BRL, Rockville, MD) and 1% penicillin-streptomycin
solution (Invitrogen, Carlsbad, CA) at 37°C in the humidi-
fied atmosphere of 95% air and 5% CO2. The cell line
underwent the authentication by DNA fingerprinting ana-
lysis with short tandem repeat markers by Korean Cell Line
Bank on November 22, 2012. For the visualization of cells
with GFP, SNUOT-Rb1 cells were transfected with cop
GFP Control Lentiviral Particles (sc-108084; Santa CruzBiotechnology, Santa Cruz, CA) according to the manufac-
turer’s instructions. To select stable clones expressing
GFP, cells were maintained in the culture media containing
4 μg/ml puromycindihydrochloride (sc-108071; Santa Cruz
Biotechnology) for 2 weeks.
Intravitreal injection of retinoblastoma cells
At 48 hpf, zebrafish embryos were anesthetized with 0.042
mg/ml Tricaine (ethyl 3-aminobenzoate methanesulfonate;
Sigma-Aldrich). Eight to 10 hours before the injection,
zebrafish embryos were dechorionated if necessary. For the
stable injection, zebrafish were placed on the 1.7% agarose
gel containing 1 ppm methylene blue. Then, using the
Pneumatic PicoPump (PV820; World Precision Instru-
ments, Sarasota, FL), cells of the indicated number were
injected into the vitreous cavity of zebrafish embryos via
glass capillaries attached to the Hamilton syringe (Hamilton
Company, Reno, NV) under the stereomicroscope (Leica
S6 E; Leica Microsystems, Wetzlar, Germany). Eyes of
zebrafish were scanned daily on the Coverglass-Bottom
dish (SPL Life Sciences, Pocheon, Republic of Korea)
by the confocal laser microscope (Fluoview FV1000;
Olympus, Tokyo, Japan) to record the alterations in the
tumor population.
Quantification of tumor population
We obtained the images of the eyeballs of zebrafish 1
hour, 24, 48, 72, 96 hours after the injection of retinoblast-
oma cells with the confocal laser microscope (Fluoview
FV1000, Olympus). The mean intensity of GFP expression
was measured using the ImageJ program (1.46r; National
Institutes of Health, Bethesda, MD) [24]. After opening
the image file captured with the confocal laser microscopy
in the program, the color threshold was set using the
menu Image>Adjust>Color Threshold. Then, the area
over the designated threshold (brightness 48) was selected
automatically with the yellow demarcation line or by
putting the ‘select’ button on the pop-up. The mean inten-
sity of GFP expression was calculated by the menu
Analyze>Tools>Color Histogram or putting the ‘RGB’ but-
ton twice on the pop-up in the menu Analyze>Histogram
to demonstrate green histogram of the image (Different ap-
proaches were required to get the values from version to
version). The values were demonstrated as ‘Mean’ or
‘gMean’ on the pop-up. Eight zebrafish were included per
group for experiments.
Isolation of retinoblastoma cells
Four days after the injection of retinoblastoma cells, about
150 zebrafish were collected in 4°C phosphate-buffered sa-
line supplemented with 1% penicillin-streptomycin solution
(Invitrogen). Then, the zebrafish were digested with 1.5
mg/ml collagenase from Clostridium histolyticum (Sigma-
Aldrich) in Hank’s balanced salt solution supplemented
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solution (Invitrogen) at 37°C for 30 minutes. The isolated
cells were suspended and incubated in RPMI 1640
(WelGENE) supplemented with 10% FBS (Gibco BRL), 1%
penicillin-streptomycin solution (Invitrogen), and 4 μg/ml
puromycindihydrochloride (Santa Cruz Biotechnology).
After the sufficient colonies were formed, we proceeded on
further analyses.
Immunoblot
The cells were lysed with RIPA buffer containing a pro-
tease inhibitor (Roche, Penzberg, Germany). The lysates
were centrifuged at 13,000 rpm at 4°C for 20 minutes.
Then, the supernatants were delivered to new micro test
tubes for further processes. Equal amounts of extracted
proteins from the cells were separated by electrophoresis
on 7.5% SDS-PAGE and transferred to nitrocellulose
membranes (AmershamHybond ECL, GE Healthcare Bio-
Sciences, Piscataway, NJ). The membranes were incubated
with anti-GFAP antibody (1:1,000, ab53554, Abcam,
Cambridge, United Kingdom), anti-NSE antibody (1:1,000,
#9536, Cell Signaling Technology, Beverly, MA), and anti-
β-actin antibody (1:3,000, A2066, Sigma-Aldrich) at 4°C
overnight. Then, the membranes were incubated with
species-specific horseradish peroxidase-conjugated sec-
ondary antibodies (Pierce, Thermo Scientific, Waltham,
MA). After the treatment of membranes with Amersham
ECL™ western blotting detection reagent (GE Healthcare
Bio-Sciences), the membranes were exposed to the film
(AmershamHyperfilm ECL, GE Healthcare Bio-Sciences).
Reverse transcriptase-polymerase chain reaction (PCR)
Total RNA was extracted from the cells using TRIzol
(Invitrogen) according to the manufacturer’s instructions.
For the synthesis of cDNA, 1 μg of total RNA was mixed
and reverse transcribed with oligo(dT)15 primer, Super-
script II reverse transcriptase (Invitrogen Corp.) and
dNTPs. Polymerase chain reaction (PCR) was performed
with the resultant cDNA, 10X PCR buffer, 2.5 mMdNTPs,
10 mM forward and reverse primers, DNA polymerase
(Corebiosystem, Seoul, Republic of Korea), and RNAse-free
water. The primers for cellular retinaldehyde-binding pro-
tein (CRALBP) were 5′-TGGCAAAGTCAAGAAATCAC
C-3′ (forward) and 5′-CGTGGACAAAGACCCTCTCA-3′
(reverse) [25], and the resultant product was 313 bp. PCR
was performed with denaturation in 5 minutes at 94°C,
followed by 35 cycles of 30 seconds of denaturation at
94°C, 30 seconds of annealing at 60°C, and 30 seconds
of elongation at 72°C. The primers for GAPDH were 5′-A
CCACAGTCCATGCCATCAC-3′ (forward) and 5′-TCC
ACCACCCTGTTGCTGTA-3′ (reverse), and the resultant
product was 500 bp. PCR was performed with denaturation
in 5 minutes at 94°C, followed by 30 cycles of 30 seconds of
denaturation at 94°C, 30 seconds of annealing at 65°C, and30 seconds of elongation at 72°C. The PCR products were
electrophoresed on 1% agarose gels containing ethidium
bromide in a constant 100 V field.
Preparation and treatment of anticancer drugs
Carboplatin (C2538) and melphalan (M2011) were pur-
chased from Sigma-Aldrich. Zebrafish were cultured in
fresh Ringer’s solution containing 200 μM anticancer
drugs after the intravitreal injection of retinoblastoma
cells. The solutions were changed every 24 hours. Eyes of
zebrafishembyos were scanned daily on the Coverglass-
Bottom dish (SPL Life Sciences) by the confocal laser
microscope (Fluoview FV1000, Olympus).
Cell viability assay
Cell viability was evaluated with 2-(4-Iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (water
soluble tetrazolium salt, WST-1) assay using EZ-Cytox
Cell Viability Assay kit (Itsbio, Seoul, Republic of Korea)
according to the manufacturer’s instruction. Briefly,
SNUOT-Rb1 cells were plated in 96 well plates and cul-
tured overnight (1 × 104 cells per well). The cells were
treated with anticancer drugs of different concentrations
(25, 50, 100, 200, 400 μM) for 48 hours. Then, the reagent
from EZ-Cytox Cell Viability Assay kit was applied to each
well. After 2 hours of additional incubation, 96 well plates
were shaken thoroughly on the shaker for 1 minute. Ab-
sorbance was measured at 450 nm using the microplate
reader (VersaMax, Molecular Devices, Sunnyvale, CA). To
confirm the results of WST-1 assay, direct estimation of
viable cells using Trypan Blue Stain (Life Technologies,
Carsbad, CA) was performed after the treatment with an-
ticancer drugs of different concentrations for 48 hours.
Statistical analysis
Differences of the values between experiments were
assessed with the Student’s t-test. All statistical analyses
were performed using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA). The mean value and the standard error
of the mean were shown in figures. P-values less than 0.05
were considered as statistically significant, and *, **, ***
were designated as P < 0.05, P < 0.001, P < 0.0001, respect-
ively, in figures.
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